Autosomal Dominant Polycystic Kidney Disease Treatment Marke

In-Depth Forecast & Analysis on Autosomal Dominant Polycystic Kidney Disease Treatment Market for 2018-2028

Kategorie der Pressemeldung: 
Mitteilung: 

Autosomal dominant polycystic kidney disease is the most common inherited kidney disease, characterized by growth of number of cysts in the kidney. Patients with autosomal dominant polycystic kidney disease generally begin to show symptoms at the age of 30-40 years and rarely in childhood. The most common symptoms of autosomal dominant polycystic kidney disease include pain in the back & sides and headache. According to NIH, autosomal dominant polycystic kidney disease affects 2-3 person per 10,000 population in Europe. Autosomal dominant polycystic kidney disease is diagnosed by kidney imaging using ultrasound, CT scans or MRI imaging. Genetic testing is done to confirm diagnosis. However, till date no cure is available for autosomal dominant polycystic kidney disease and treatment is mainly aimed at symptomatic relief. Symptomatic treatment for autosomal dominant polycystic kidney disease involves pain medications, removal of kidney cysts, controlling high blood pressure and acidosis, restricting progression of kidney failure etc. Along with pharmacological treatment diet control is recommended to slow down the progression of autosomal dominant polycystic kidney disease. Recently in 2018, U.S. Food and Drug Administration (FDA) approved first and only treatment Tolvaptan to retard the progression of autosomal dominant polycystic kidney disease.